vs

Side-by-side financial comparison of MESABI TRUST (MSB) and TScan Therapeutics, Inc. (TCRX). Click either name above to swap in a different company.

MESABI TRUST is the larger business by last-quarter revenue ($3.6M vs $2.6M, roughly 1.4× TScan Therapeutics, Inc.). MESABI TRUST runs the higher net margin — 77.1% vs -895.1%, a 972.2% gap on every dollar of revenue. On growth, TScan Therapeutics, Inc. posted the faster year-over-year revenue change (286.0% vs -95.5%). Over the past eight quarters, TScan Therapeutics, Inc.'s revenue compounded faster (-9.7% CAGR vs -24.1%).

Mesabi Trust is a United States-based royalty trust that holds permanent royalty interests in iron ore mining properties located in Minnesota's Mesabi Range. It earns revenue primarily from royalty payments tied to the production and sale of iron ore products, with core earnings sourced from active mining partners operating on the land it holds interests in, catering to the global steel manufacturing market.

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.

MSB vs TCRX — Head-to-Head

Bigger by revenue
MSB
MSB
1.4× larger
MSB
$3.6M
$2.6M
TCRX
Growing faster (revenue YoY)
TCRX
TCRX
+381.5% gap
TCRX
286.0%
-95.5%
MSB
Higher net margin
MSB
MSB
972.2% more per $
MSB
77.1%
-895.1%
TCRX
Faster 2-yr revenue CAGR
TCRX
TCRX
Annualised
TCRX
-9.7%
-24.1%
MSB

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
MSB
MSB
TCRX
TCRX
Revenue
$3.6M
$2.6M
Net Profit
$2.8M
$-23.0M
Gross Margin
77.1%
Operating Margin
-929.4%
Net Margin
77.1%
-895.1%
Revenue YoY
-95.5%
286.0%
Net Profit YoY
-96.5%
35.8%
EPS (diluted)
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MSB
MSB
TCRX
TCRX
Q4 25
$3.6M
$2.6M
Q3 25
$5.6M
$2.5M
Q2 25
$4.7M
$3.1M
Q1 25
$6.9M
$2.2M
Q4 24
$79.0M
Q3 24
$6.5M
$1.0M
Q2 24
$6.3M
Q1 24
$6.2M
Net Profit
MSB
MSB
TCRX
TCRX
Q4 25
$2.8M
$-23.0M
Q3 25
$4.7M
$-35.7M
Q2 25
$3.6M
$-37.0M
Q1 25
$6.1M
$-34.1M
Q4 24
$78.3M
Q3 24
$5.4M
$-29.9M
Q2 24
$3.5M
Q1 24
$4.7M
Gross Margin
MSB
MSB
TCRX
TCRX
Q4 25
77.1%
Q3 25
84.6%
Q2 25
76.7%
Q1 25
88.5%
Q4 24
99.1%
Q3 24
83.2%
Q2 24
55.7%
Q1 24
75.3%
Operating Margin
MSB
MSB
TCRX
TCRX
Q4 25
-929.4%
Q3 25
-1475.6%
Q2 25
-1256.6%
Q1 25
-1669.7%
Q4 24
Q3 24
-3109.8%
Q2 24
Q1 24
Net Margin
MSB
MSB
TCRX
TCRX
Q4 25
77.1%
-895.1%
Q3 25
84.6%
-1422.1%
Q2 25
76.7%
-1201.3%
Q1 25
88.5%
-1571.9%
Q4 24
99.1%
Q3 24
83.2%
-2849.1%
Q2 24
55.7%
Q1 24
75.3%
EPS (diluted)
MSB
MSB
TCRX
TCRX
Q4 25
$-0.18
Q3 25
$-0.28
Q2 25
$-0.28
Q1 25
$-0.26
Q4 24
Q3 24
$-0.25
Q2 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MSB
MSB
TCRX
TCRX
Cash + ST InvestmentsLiquidity on hand
$152.4M
Total DebtLower is stronger
$32.5M
Stockholders' EquityBook value
$21.1M
$123.1M
Total Assets
$26.0M
$228.8M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MSB
MSB
TCRX
TCRX
Q4 25
$152.4M
Q3 25
$184.5M
Q2 25
$218.0M
Q1 25
$251.7M
Q4 24
Q3 24
$271.1M
Q2 24
Q1 24
Total Debt
MSB
MSB
TCRX
TCRX
Q4 25
$32.5M
Q3 25
$32.4M
Q2 25
$32.3M
Q1 25
$32.2M
Q4 24
Q3 24
$30.6M
Q2 24
Q1 24
Stockholders' Equity
MSB
MSB
TCRX
TCRX
Q4 25
$21.1M
$123.1M
Q3 25
$22.8M
$144.0M
Q2 25
$19.6M
$176.7M
Q1 25
$23.3M
$210.2M
Q4 24
$95.3M
Q3 24
$22.1M
$229.1M
Q2 24
$20.7M
Q1 24
$21.0M
Total Assets
MSB
MSB
TCRX
TCRX
Q4 25
$26.0M
$228.8M
Q3 25
$24.8M
$262.2M
Q2 25
$27.4M
$298.6M
Q1 25
$101.7M
$332.7M
Q4 24
$100.7M
Q3 24
$26.2M
$348.0M
Q2 24
$25.1M
Q1 24
$26.7M
Debt / Equity
MSB
MSB
TCRX
TCRX
Q4 25
0.26×
Q3 25
0.23×
Q2 25
0.18×
Q1 25
0.15×
Q4 24
Q3 24
0.13×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MSB
MSB
TCRX
TCRX
Operating Cash FlowLast quarter
$3.5M
$-32.0M
Free Cash FlowOCF − Capex
$-32.2M
FCF MarginFCF / Revenue
-1253.3%
Capex IntensityCapex / Revenue
6.7%
Cash ConversionOCF / Net Profit
1.27×
TTM Free Cash FlowTrailing 4 quarters
$-139.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MSB
MSB
TCRX
TCRX
Q4 25
$3.5M
$-32.0M
Q3 25
$4.4M
$-32.5M
Q2 25
$2.1M
$-33.3M
Q1 25
$93.9M
$-37.6M
Q4 24
$78.2M
Q3 24
$3.8M
$-27.9M
Q2 24
$2.5M
Q1 24
$14.6M
Free Cash Flow
MSB
MSB
TCRX
TCRX
Q4 25
$-32.2M
Q3 25
$-33.9M
Q2 25
$-34.5M
Q1 25
$-39.1M
Q4 24
Q3 24
$-29.3M
Q2 24
Q1 24
FCF Margin
MSB
MSB
TCRX
TCRX
Q4 25
-1253.3%
Q3 25
-1349.6%
Q2 25
-1123.1%
Q1 25
-1801.8%
Q4 24
Q3 24
-2792.0%
Q2 24
Q1 24
Capex Intensity
MSB
MSB
TCRX
TCRX
Q4 25
6.7%
Q3 25
56.8%
Q2 25
41.6%
Q1 25
70.6%
Q4 24
Q3 24
130.6%
Q2 24
Q1 24
Cash Conversion
MSB
MSB
TCRX
TCRX
Q4 25
1.27×
Q3 25
0.92×
Q2 25
0.57×
Q1 25
15.48×
Q4 24
1.00×
Q3 24
0.71×
Q2 24
0.72×
Q1 24
3.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons